{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:06:51Z","timestamp":1793783211426,"version":"4.6.1"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1001\/jamacardio.2021.3070","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:33:05Z","timestamp":1629891185000},"page":"1267","source":"Crossref","is-referenced-by-count":218,"title":["Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"6","author":[{"given":"Omar F.","family":"AbouEzzeddine","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed U.","family":"Fayyaz","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wells","family":"Askew","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"McKie","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Noseworthy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Dunlay","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panithaya","family":"Chareonthaitawee","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique L.","family":"Roger","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi210056r1","first-page":"897","article-title":"Heart failure with preserved ejection fraction.","volume":"376","author":"Redfield","year":"2017","journal-title":"N Engl J Med"},{"key":"hoi210056r2","author":"Dunlay","year":"2017"},{"issue":"6","key":"hoi210056r3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/CIRCHEARTFAILURE.112.968594","article-title":"Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.","volume":"5","author":"Mohammed","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"6","key":"hoi210056r4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00424-014-1480-8","article-title":"Heart failure with preserved ejection fraction.","volume":"466","author":"Gladden","year":"2014","journal-title":"Pflugers Arch"},{"issue":"22","key":"hoi210056r5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi210056r6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi210056r7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"38","key":"hoi210056r8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi210056r9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis.","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"24","key":"hoi210056r10","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"hoi210056r11","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"hoi210056r12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.","volume":"87","author":"St Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"hoi210056r13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1086\/496902","article-title":"High-resolution whole-genome association study of Parkinson disease.","volume":"77","author":"Maraganore","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"12","key":"hoi210056r14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.mayocp.2012.08.012","article-title":"History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.","volume":"87","author":"Rocca","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"hoi210056r15"},{"issue":"18","key":"hoi210056r16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community.","volume":"296","author":"Bursi","year":"2006","journal-title":"JAMA"},{"issue":"13","key":"hoi210056r17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi210056r18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"hoi210056r19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.mayocp.2019.11.028","article-title":"Participation bias in a survey of community patients with heart failure.","volume":"95","author":"Simsek","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"hoi210056r20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction.","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"hoi210056r21","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"hoi210056r22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hoi210056r24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"2","key":"hoi210056r25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"hoi210056r23","unstructured":"Screening for Cardiac Amyloidosis Using Nuclear Imaging for Minority Populations (SCAN-MP). ClinicalTrials.gov identifier: NCT03812172. Accessed July 15, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03812172?"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2783400\/jamacardiology_abouezzeddine_2021_oi_210056_1635348671.71407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T11:01:14Z","timestamp":1636369274000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2783400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.3070","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}